|
Post by JHam on Aug 16, 2016 14:56:37 GMT
I decided to lock in my approximate 50% gain and sold my remaining position in MEIP this morning between $2.00 and $2.05. Was hoping for more. I listened to the webcast this morning (link below), and while the news is still very promising for the longer-term, I don't see more major near-term catalysts besides the start of 2 Phase 1 trials in September, which normally are not pps moving catalysts. There still could be some analyst upgrades and more institutional buying coming, but I'm not sure how much more it'll run (if it does) in the near-term. Other reasons for my decision to lock in gains are listed below... - The Phase 3 Prac trial was guided to take 2.5 years to complete enrollment, and another 1.5 years before releasing results. - MEIP will have to help fund the Phase 2 MDS trial - No clarity given on when the $444M milestone payments will start flowing. They could be more back-ended. - Small dilutive SEC filing will be released for the partner's equity investment, which will be done at $1.90ish, which is lower than the current pps. Market may not like that news now that the partnership news has been released. investor.meipharma.com/2016-08-10-MEI-Pharma-to-Present-at-Wedbush-PacGrow-Healthcare-ConferenceGreat job!
|
|
|
Post by RLC on Aug 17, 2016 20:35:49 GMT
I decided to lock in my approximate 50% gain and sold my remaining position in MEIP this morning between $2.00 and $2.05. Was hoping for more. I listened to the webcast this morning (link below), and while the news is still very promising for the longer-term, I don't see more major near-term catalysts besides the start of 2 Phase 1 trials in September, which normally are not pps moving catalysts. There still could be some analyst upgrades and more institutional buying coming, but I'm not sure how much more it'll run (if it does) in the near-term. Other reasons for my decision to lock in gains are listed below... - The Phase 3 Prac trial was guided to take 2.5 years to complete enrollment, and another 1.5 years before releasing results. - MEIP will have to help fund the Phase 2 MDS trial - No clarity given on when the $444M milestone payments will start flowing. They could be more back-ended. - Small dilutive SEC filing will be released for the partner's equity investment, which will be done at $1.90ish, which is lower than the current pps. Market may not like that news now that the partnership news has been released. investor.meipharma.com/2016-08-10-MEI-Pharma-to-Present-at-Wedbush-PacGrow-Healthcare-ConferenceCongrats on the trade! I was a little surprised to see you sell this one so soon. I'm holding tight here for the near term, in hopes they get some analyst upgrades and increased institutional ownership. FWIW, 8-K was released revealing the details of the stock purchase agreement with Helsinn: 2,616,431 shares @ $1.911/share
|
|
|
Post by stargazer on Aug 17, 2016 21:41:00 GMT
I decided to lock in my approximate 50% gain and sold my remaining position in MEIP this morning between $2.00 and $2.05. Was hoping for more. I listened to the webcast this morning (link below), and while the news is still very promising for the longer-term, I don't see more major near-term catalysts besides the start of 2 Phase 1 trials in September, which normally are not pps moving catalysts. There still could be some analyst upgrades and more institutional buying coming, but I'm not sure how much more it'll run (if it does) in the near-term. Other reasons for my decision to lock in gains are listed below... - The Phase 3 Prac trial was guided to take 2.5 years to complete enrollment, and another 1.5 years before releasing results. - MEIP will have to help fund the Phase 2 MDS trial - No clarity given on when the $444M milestone payments will start flowing. They could be more back-ended. - Small dilutive SEC filing will be released for the partner's equity investment, which will be done at $1.90ish, which is lower than the current pps. Market may not like that news now that the partnership news has been released. investor.meipharma.com/2016-08-10-MEI-Pharma-to-Present-at-Wedbush-PacGrow-Healthcare-ConferenceCongrats on the trade! I was a little surprised to see you sell this one so soon. I'm holding tight here for the near term, in hopes they get some analyst upgrades and increased institutional ownership. FWIW, 8-K was released revealing the details of the stock purchase agreement with Helsinn: 2,616,431 shares @ $1.911/shareWorks out to about a 7.5% stake in the company to Helsinn.
|
|
|
Post by jckrdu on Aug 18, 2016 2:02:03 GMT
I decided to lock in my approximate 50% gain and sold my remaining position in MEIP this morning between $2.00 and $2.05. Was hoping for more. I listened to the webcast this morning (link below), and while the news is still very promising for the longer-term, I don't see more major near-term catalysts besides the start of 2 Phase 1 trials in September, which normally are not pps moving catalysts. There still could be some analyst upgrades and more institutional buying coming, but I'm not sure how much more it'll run (if it does) in the near-term. Other reasons for my decision to lock in gains are listed below... - The Phase 3 Prac trial was guided to take 2.5 years to complete enrollment, and another 1.5 years before releasing results. - MEIP will have to help fund the Phase 2 MDS trial - No clarity given on when the $444M milestone payments will start flowing. They could be more back-ended. - Small dilutive SEC filing will be released for the partner's equity investment, which will be done at $1.90ish, which is lower than the current pps. Market may not like that news now that the partnership news has been released. investor.meipharma.com/2016-08-10-MEI-Pharma-to-Present-at-Wedbush-PacGrow-Healthcare-ConferenceCongrats on the trade! I was a little surprised to see you sell this one so soon. I'm holding tight here for the near term, in hopes they get some analyst upgrades and increased institutional ownership. FWIW, 8-K was released revealing the details of the stock purchase agreement with Helsinn: 2,616,431 shares @ $1.911/shareI hear you RLC. The reasons stated above and another opportunity with near-term potential carried the day.
Hope it keeps running for everyone still holding.
|
|
|
Post by stargazer on May 25, 2017 16:33:06 GMT
JCK / RLC
You guys still following this one?
JCK your call in Aug 16 was spot on! It has been a sleeper since that time but it looks like coming back to life since the past couple of days.
However,I could not find any reasons for the current price rise - may have missed some news item.
|
|
|
Post by jckrdu on May 25, 2017 16:43:53 GMT
JCK / RLC You guys still following this one? JCK your call in Aug 16 was spot on! It has been a sleeper since that time but it looks like coming back to life since the past couple of days. However,I could not find any reasons for the current price rise - may have missed some news item. Still following, but not in this one at the moment. Oppenheimer gave a $6.50 price target this morning.
|
|
|
Post by RLC on May 25, 2017 17:04:35 GMT
JCK / RLC You guys still following this one? JCK your call in Aug 16 was spot on! It has been a sleeper since that time but it looks like coming back to life since the past couple of days. However,I could not find any reasons for the current price rise - may have missed some news item. I pulled my large position out a while back to pursue some other opportunities, but have jumped in and out this a few times more recently with small money. Unfortunately, I had no position on this recent jump. I know they're releasing some Phase 2 data at ASCO, which could be a nice catalyst to get them closer to that $6.50 PT jckrdu mentioned. To be honest I'm a little mad at myself for not holding a core position in this. Everything lined up and the deal with Helsinn really solidified the company and removed quite a bit of risk. I'm going to do some deeper DD (get refreshed on everything) and might try to load up a core position while it's still around these levels.
|
|
|
Post by stargazer on May 25, 2017 17:28:09 GMT
JCK / RLC You guys still following this one? JCK your call in Aug 16 was spot on! It has been a sleeper since that time but it looks like coming back to life since the past couple of days. However,I could not find any reasons for the current price rise - may have missed some news item. Still following, but not in this one at the moment. Oppenheimer gave a $6.50 price target this morning. Thanks JCK and RLC I missed the Oppenheimer price target - that was the reason for this rise. May not sustain unless some good information comes out at ASCO early next month.
|
|
|
Post by stargazer on Jun 5, 2018 17:14:40 GMT
RLC / JCK
You guys still following this one? It has been pretty strong since the past 2 weeks. Tempted to book profits here
|
|